NEXTCURE, INC Research and Development Expense
NEXTCURE, INC (NXTC) reported Research and Development Expense of $7.42 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-18
- NEXTCURE, INC research and development expense for the quarter ending 2026-06-30 was $7.42M, a 69.18% decline year-over-year.
- NEXTCURE, INC research and development expense for the quarter ending 2026-03-31 was $6.83M, a 13.45% decline year-over-year.
- NEXTCURE, INC research and development expense for the quarter ending 2025-12-31 was $6.80M, a 23.61% decline year-over-year.
- NEXTCURE, INC research and development expense for the quarter ending 2025-09-30 was $6.14M, a 30.03% decline year-over-year.
- NEXTCURE, INC research and development expense for fiscal 2023 was $47.93M, a 11.56% decline from fiscal 2022.
- NEXTCURE, INC research and development expense for fiscal 2022 was $54.20M, a 7.98% increase from fiscal 2021.
- NEXTCURE, INC research and development expense for fiscal 2021 was $50.19M, a 7.81% increase from fiscal 2020.
- NEXTCURE, INC research and development expense for fiscal 2020 was $46.55M, a 36.06% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.42M S-4 · filed 2026-08-18 | $14.26M S-4 · filed 2026-08-18 | $21.06M derived: sum of 3 quarters · filed 2026-08-18 | $27.20M derived: sum of 4 quarters · filed 2026-08-18 |
| 2026-03-31 | $6.83M 10-Q · filed 2026-05-07 | $13.63M derived: sum of 2 quarters · filed 2026-08-18 | $19.77M derived: sum of 3 quarters · filed 2026-08-18 | $43.86M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-12-31 | $6.80M derived: S-4 12 month − 10-Q 9 month · filed 2026-08-18 | $12.94M derived: sum of 2 quarters · filed 2026-08-18 | $37.03M derived: sum of 3 quarters · filed 2026-08-18 | $44.92M S-4 · filed 2026-08-18 |
| 2025-09-30 | $6.14M 10-Q · filed 2025-11-05 | $30.23M derived: sum of 2 quarters · filed 2026-08-18 | $38.12M 10-Q · filed 2025-11-05 | $47.02M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-06-30 | $24.09M S-4 · filed 2026-08-18 | $31.99M S-4 · filed 2026-08-18 | $40.89M derived: sum of 3 quarters · filed 2026-08-18 | $49.66M derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-03-31 | $7.90M 10-Q · filed 2026-05-07 | $16.80M derived: sum of 2 quarters · filed 2026-08-18 | $25.57M derived: sum of 3 quarters · filed 2026-08-18 | $37.99M derived: sum of 4 quarters · filed 2026-08-18 |
| 2024-12-31 | $8.90M derived: S-4 12 month − 10-Q 9 month · filed 2026-08-18 | $17.67M derived: sum of 2 quarters · filed 2026-08-18 | $30.09M derived: sum of 3 quarters · filed 2026-08-18 | $41.49M S-4 · filed 2026-08-18 |
| 2024-09-30 | $8.77M 10-Q · filed 2025-11-05 | $21.19M derived: sum of 2 quarters · filed 2025-11-05 | $32.59M 10-Q · filed 2025-11-05 | $44.41M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $12.42M 10-Q · filed 2025-08-07 | $23.82M 10-Q · filed 2025-08-07 | $35.64M derived: sum of 3 quarters · filed 2025-08-07 | $46.65M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $11.40M 10-Q · filed 2025-05-01 | $23.23M derived: sum of 2 quarters · filed 2025-05-01 | $34.23M derived: sum of 3 quarters · filed 2025-05-01 | $47.68M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $22.84M derived: sum of 2 quarters · filed 2025-03-06 | $36.28M derived: sum of 3 quarters · filed 2025-03-06 | $47.93M 10-K · filed 2025-03-06 |
| 2023-09-30 | $11.01M 10-Q · filed 2024-11-07 | $24.46M derived: sum of 2 quarters · filed 2024-11-07 | $36.10M 10-Q · filed 2024-11-07 | $48.93M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $13.45M 10-Q · filed 2024-08-01 | $25.09M 10-Q · filed 2024-08-01 | $37.92M derived: sum of 3 quarters · filed 2024-08-01 | $51.44M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $11.65M 10-Q · filed 2024-05-02 | $24.47M derived: sum of 2 quarters · filed 2024-05-02 | $38.00M derived: sum of 3 quarters · filed 2024-05-02 | $50.82M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $12.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $26.35M derived: sum of 2 quarters · filed 2024-03-21 | $39.17M derived: sum of 3 quarters · filed 2024-03-21 | $54.20M 10-K · filed 2024-03-21 |
| 2022-09-30 | $13.53M 10-Q · filed 2023-11-02 | $26.35M derived: sum of 2 quarters · filed 2023-11-02 | $41.38M 10-Q · filed 2023-11-02 | $53.64M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $12.82M 10-Q · filed 2023-08-03 | $27.85M 10-Q · filed 2023-08-03 | $40.11M derived: sum of 3 quarters · filed 2023-08-03 | $53.71M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $15.02M 10-Q · filed 2023-05-04 | $27.29M derived: sum of 2 quarters · filed 2023-05-04 | $40.88M derived: sum of 3 quarters · filed 2023-05-04 | $52.83M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $12.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $25.86M derived: sum of 2 quarters · filed 2023-03-02 | $37.81M derived: sum of 3 quarters · filed 2023-03-02 | $50.19M 10-K · filed 2023-03-02 |
| 2021-09-30 | $13.60M 10-Q · filed 2022-11-03 | $25.54M derived: sum of 2 quarters · filed 2022-11-03 | $37.93M 10-Q · filed 2022-11-03 | $50.03M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $11.95M 10-Q · filed 2022-08-04 | $24.33M 10-Q · filed 2022-08-04 | $36.44M derived: sum of 3 quarters · filed 2022-08-04 | $49.18M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $12.39M 10-Q · filed 2022-05-05 | $24.49M derived: sum of 2 quarters · filed 2022-05-05 | $37.23M derived: sum of 3 quarters · filed 2022-05-05 | $48.36M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $12.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $24.85M derived: sum of 2 quarters · filed 2022-03-03 | $35.98M derived: sum of 3 quarters · filed 2022-03-03 | $46.55M 10-K · filed 2022-03-03 |
| 2020-09-30 | $12.74M 10-Q · filed 2021-11-04 | $23.87M derived: sum of 2 quarters · filed 2021-11-04 | $34.45M 10-Q · filed 2021-11-04 | $45.84M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $11.13M 10-Q · filed 2021-08-05 | $21.71M 10-Q · filed 2021-08-05 | $33.10M derived: sum of 3 quarters · filed 2021-08-05 | $41.77M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $10.58M 10-Q · filed 2021-05-06 | $21.98M derived: sum of 2 quarters · filed 2021-05-06 | $30.64M derived: sum of 3 quarters · filed 2021-05-06 | $38.28M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $11.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $20.06M derived: sum of 2 quarters · filed 2021-03-04 | $27.70M derived: sum of 3 quarters · filed 2021-03-04 | $34.22M 10-K · filed 2021-03-04 |
| 2019-09-30 | $8.66M 10-Q · filed 2020-11-05 | $16.31M derived: sum of 2 quarters · filed 2020-11-05 | $22.82M 10-Q · filed 2020-11-05 | $29.07M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $7.64M 10-Q · filed 2020-08-06 | $14.16M 10-Q · filed 2020-08-06 | $20.40M derived: sum of 3 quarters · filed 2020-08-06 | $25.30M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $6.51M 10-Q · filed 2020-05-07 | $12.76M derived: sum of 2 quarters · filed 2020-05-07 | $17.66M derived: sum of 3 quarters · filed 2020-05-07 | $22.09M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $11.14M derived: sum of 2 quarters · filed 2020-03-12 | $15.58M derived: sum of 3 quarters · filed 2020-03-12 | $19.79M 10-K · filed 2020-03-12 |
| 2018-09-30 | $4.89M 10-Q · filed 2019-11-12 | $9.33M derived: sum of 2 quarters · filed 2019-11-12 | $13.54M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $4.43M 10-Q · filed 2019-08-12 | $8.64M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $4.21M 10-Q · filed 2019-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |